NCT01992965

Brief Summary

The purpose of the study is to evaluate the effect of real-time continuous glucose monitoring system on glucose control and outcomes of critically ill patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
144

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Apr 2014

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 13, 2013

Completed
12 days until next milestone

First Posted

Study publicly available on registry

November 25, 2013

Completed
4 months until next milestone

Study Start

First participant enrolled

April 1, 2014

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2016

Completed
Last Updated

May 7, 2014

Status Verified

May 1, 2014

Enrollment Period

2.1 years

First QC Date

November 13, 2013

Last Update Submit

May 6, 2014

Conditions

Keywords

continuous glucose monitoring;critically ill;

Outcome Measures

Primary Outcomes (1)

  • Glycemic Control Measures including: Percentage of target blood glucose levels (defined as between 8mmol/L and 10mmol/L); Time of hyperglycemia (defined as >10mmol/L); Hypoglycemia rate (defined as < 2.2mmol/L); Glucose lability index

    Glycemic control measures will be assessed up to five days.

Secondary Outcomes (2)

  • Prognosis Measures including: Duration of mechanical ventilation;Time of ICU stay; Time of hospital stay; 28 days - mortality rate

    All the participants will be followed for the duration of hospital stay or 28 days.

  • Cost

    Cost associated with glucose monitoring

Study Arms (2)

Continuous Glucose Monitoring Group

EXPERIMENTAL

Continuous Glucose Monitoring Group: Different methods of blood glucose monitoring between groups, and this group will use real-time continuous glucose monitoring system with alarm limits(high and low limit is 10 mmol/L and 8 mmil/L , respectively ) up to five days for glucose control, the target mean glucose level is between 8 and 10 mmol/L.

Other: Different methods of blood glucose monitoring between groups

Conventional Group

ACTIVE COMPARATOR

Conventional Group: Different methods of blood glucose monitoring between groups, and this group will use finger prick blood glucose measurements for glucose control with the same target mean glucose level of 8 -10 mmol/L. Patients also wear real-time continuous glucose monitoring system to collect glucose measurements. The values of real-time continuous glucose monitoring system are blinded to investigator and patients.

Other: Different methods of blood glucose monitoring between groups

Interventions

Finger prick blood glucose in conventional group versus real-time continuous glucose monitoring system of continuous glucose monitoring group

Continuous Glucose Monitoring GroupConventional Group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • More than 18 years old male or female;
  • Expected ICU stays longer than 72 hours;
  • Glucose level more than 8 mmol/L when enrolls in the ICU;
  • Patients or their legal surrogates have signed the informed consent.

You may not qualify if:

  • Pregnant or lactating women;
  • ICU stays less than 72 hours;
  • Usage of real-time continuous glucose monitoring system is considered as a contraindication.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Intensive care unit of West China Hospital

Chengdu, Sichuan, 610000, China

RECRUITING

MeSH Terms

Conditions

HyperglycemiaCritical Illness

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Yan Kang, MD

    West China Hospital

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Director of Intensive Care Unit

Study Record Dates

First Submitted

November 13, 2013

First Posted

November 25, 2013

Study Start

April 1, 2014

Primary Completion

May 1, 2016

Study Completion

May 1, 2016

Last Updated

May 7, 2014

Record last verified: 2014-05

Locations